Using Fexofenadine to Help Treat Parkinson's Disease
Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment
PHASE2; PHASE3 · Tanta University · NCT06785298
This study is testing if adding Fexofenadine to the usual Parkinson's treatment can help improve symptoms for people with the disease.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 50 Years to 70 Years |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Tanta) |
| Trial ID | NCT06785298 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Fexofenadine as an adjuvant therapy for patients with Parkinson's disease, a progressive neurological disorder. The study aims to assess the efficacy of Fexofenadine in combination with standard dopamine replacement therapy, such as Levodopa/carbidopa, in improving both motor and non-motor symptoms of the disease. Participants will be evaluated based on their response to treatment over the course of the trial, which includes phases 2 and 3 to ensure comprehensive data collection and analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 50 and older who have been diagnosed with Parkinson's disease and are currently on dopamine replacement therapy.
Not a fit: Patients with atypical parkinsonism, significant liver or kidney dysfunction, or those with a known allergy to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance the quality of life for patients with Parkinson's disease by improving their symptoms.
How similar studies have performed: While the use of Fexofenadine in this context is novel, other studies have explored various adjuvant therapies for Parkinson's disease with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:• Age ≥ 50 years. Both male and female will be included. Patients with Parkinson's disease on dopamine replacement therapy. Modified Hoehn and Yahr stage, MHY 1-4 Exclusion Criteria:• Atypical parkinsonism or drug-induced parkinsonism Breast feeding Pregnant women and women with planned pregnancy. Patients with significant liver and kidney function abnormalities. History/presence of acute heart disease Alcohol and / or drug abusers. Patients with known allergy to the study medications Other medical conditions that can interfere with results or endanger the participant.
Where this trial is running
Tanta
- Tanta University — Tanta, Egypt (RECRUITING)
Study contacts
- Study coordinator: Ihab Elsayed Hassan, Doctor
- Email: ihassan@horus.edu.eg
- Phone: 0201067831661
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Parkinson Disease, Fexofenadine